© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
The oncologist from Children's Hospital of Philadelphia discussed long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
Review top news and interview highlights from the week ending August 12, 2022.
The FDA recently accepted the company’s BLA for omidubicel for priority review.